United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
ROCKVILLE, MD, May 07, 2018 --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at Deutsche Bank's 43rd Annual Health Care Conference in Boston on May 8, 2018 at 8:00 am (ET).
A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, [email protected] Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, [email protected]
